Agios Pharmaceuticals Inc (NASDAQ:AGIO) price on Friday, April 11, rose 5.49% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $26.70.
A look at the stock’s price movement, the close in the last trading session was $25.31, moving within a range at $25.0 and $26.92. The beta value (5-Year monthly) was 0.828 while the PE ratio in trailing twelve months stood at 2.34. Turning to its 52-week performance, $62.58 and $23.42 were the 52-week high and 52-week low respectively. Overall, AGIO moved -14.07% over the past month.
Agios Pharmaceuticals Inc’s market cap currently stands at around $1.53 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-12.
Analysts have a consensus estimate of 9.73M for the company’s revenue for the quarter, with a low and high estimate of 8.99M and 10.4M respectively. The average forecast suggests up to a 18.78% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 51.16M, representing a 40.18% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AGIO is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 4 recommend AGIO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AGIO’s current price about -8.06% and -15.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.03, while 7-day volatility ratio is 10.59% and 6.31% in the 30-day chart. Further, Agios Pharmaceuticals Inc (AGIO) has a beta value of 0.82, and an average true range (ATR) of 1.90. Analysts have given the company’s stock an average 52-week price target of $51, forecast between a low of $51 and high of $51. Looking at the price targets, the low is -91.01% off current price level while to achieve the yearly target high, price needs to move -91.01%. Nonetheless, investors will most likely welcome a -91.01% jump to $51 which is the analysts’ median price.
If we refocus on Agios Pharmaceuticals Inc (NASDAQ:AGIO), historical trading data shows that trading volumes averaged 0.89 over the past 10 days and 702.58K over the past 3 months. The company’s latest data on shares outstanding shows there are 57.16 million shares.
The 3.71% of Agios Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 106.75% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.4 million on 2025-03-14, giving us a short ratio of 4.77. The data shows that as of 2025-03-14 short interest in Agios Pharmaceuticals Inc (AGIO) stood at 603.00004 of shares outstanding, with shares short falling to 4.63 million registered in 2025-02-14. Current price change has pushed the stock -18.75% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AGIO stock continues to rise going into the next quarter.
